Company: INTS
Filing Date: 2025-04-25
Form Type: 8-K
Source: 0001628280-25-020057
Chunk: 4

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-04-25
Form: 8-K
Item: Item 9.01
Chunk 4
---
Item 9.01. Financial Statements and Exhibits

(d) Exhibits

  Exhibit No.      Description                                                                                                                                                                                           
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
          1.1      Form of Placement Agent Agreement dated April 24, 2025, by and between the Company and A. G. P./Alliance Global Partners and Brookline Capital Markets, a division of Arcadia Securities, LLC (in...  
          4.1      Form of Series B-1 Common Warrant.                                                                                                                                                                    
          4.2      Form of Series B-2 Common Warrant.                                                                                                                                                                    
         10.1      Form of Securities Purchase Agreement, dated as of April 2 4, 2025, by and between Intensity Therapeutics, Inc. and the purchasers party thereto.                                                     
         99.1      Pricing Press Release, dated April 25, 2025.                                                                                                                                                          
          104      Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)                                                                                                              

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  Intensity Therapeutics, Inc.                                                                 
  Dated: April 25, 2025             By:      /s/ Lewis H. Bender                               
                                             Name:                    Lewis H. Bender          
                                             Title:                   Chief Executive Officer